A detailed history of Cary Street Partners Investment Advisory LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Cary Street Partners Investment Advisory LLC holds 24,220 shares of VRTX stock, worth $12.2 Million. This represents 0.43% of its overall portfolio holdings.

Number of Shares
24,220
Previous 24,385 0.68%
Holding current value
$12.2 Million
Previous $11.4 Million 1.44%
% of portfolio
0.43%
Previous 0.47%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

SELL
$460.0 - $505.78 $75,900 - $83,453
-165 Reduced 0.68%
24,220 $11.3 Million
Q2 2024

Jul 22, 2024

BUY
$392.81 - $485.53 $292,643 - $361,719
745 Added 3.15%
24,385 $11.4 Million
Q1 2024

Apr 30, 2024

BUY
$407.69 - $446.08 $154,106 - $168,618
378 Added 1.62%
23,640 $9.88 Million
Q4 2023

Feb 07, 2024

BUY
$343.0 - $410.68 $7.98 Million - $9.55 Million
23,262 New
23,262 $9.47 Million
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $185,660 - $198,990
549 Added 2.47%
22,744 $7.91 Million
Q2 2023

Aug 10, 2023

BUY
$314.42 - $351.91 $1.89 Million - $2.12 Million
6,011 Added 37.14%
22,195 $7.81 Million
Q1 2023

May 12, 2023

BUY
$283.23 - $323.1 $120,939 - $137,963
427 Added 2.71%
16,184 $5.1 Million
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $1.57 Million - $1.76 Million
5,489 Added 53.46%
15,757 $4.55 Million
Q3 2022

Nov 14, 2022

BUY
$273.83 - $305.53 $2.81 Million - $3.14 Million
10,268 New
10,268 $2.97 Million
Q4 2020

Feb 12, 2021

SELL
$207.01 - $276.09 $4,968 - $6,626
-24 Closed
0 $0
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $6,135 - $7,274
24 New
24 $7,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Cary Street Partners Investment Advisory LLC Portfolio

Follow Cary Street Partners Investment Advisory LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cary Street Partners Investment Advisory LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cary Street Partners Investment Advisory LLC with notifications on news.